[ad_1]
January 12, 2024 9:47 AM EST
A preliminary evaluate of unintended effects from common medication used to deal with diabetes and weight problems exhibits no hyperlink with suicidal ideas or actions, the U.S. Meals and Drug Administration stated Thursday.
However the company additionally stated officers can’t definitively rule out that “a small threat might exist” and that they will proceed to look into experiences concerning greater than a dozen medication, together with Ozempic, Wegovy, and Mounjaro. Sufferers taking the medication ought to report any issues to well being care suppliers, the FDA stated.
The evaluate follows a latest federally funded examine that confirmed that folks taking semaglutide, the treatment in Ozempic and Wegovy, had a decrease threat of suicidal ideas than these taking different medication to deal with weight problems and diabetes. The evaluate got here after European regulators stated they had been investigating anecdotal experiences that folks taking semaglutide had ideas of self-harm.
“Our preliminary analysis has not discovered proof that use of those medicines causes suicidal ideas or actions,” the FDA report stated.
The company is analyzing experiences associated to greater than a dozen medication accredited since 2005 which can be often called GLP-1 receptor agonists. The drugs assist management blood sugar ranges and scale back the danger of coronary heart illness in folks with sort 2 diabetes. A few of the medication are additionally used to assist folks with weight problems or who’re obese shed kilos.
[ad_2]
Source link